+1 (315) 215-3225

+1 (315) 215-3225
Lanadelumab - Launch Insight, 2019
Published Date: February 2019
Report Code: DELV-Laun-33
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Lanadelumab Launch Insight 2019

Lanadelumab - Launch Insight, 2019

Code: DELV-Laun-33
February 2019
50 Pages
Region: Global,
Table of Content
Tables & Figures

DelveInsight’s, “Lanadelumab, Launch Insight, 2019” report provides comprehensive Insight about the Lanadelumab's launch. The report covers all the indications for which the Lanadelumab is being developed and also provides the competitive landscape for the major indications. The report further includes patent details, forecasted sales till 2022 and post launch market positioning.

The report will provide a clear picture of market positioning of the upcoming launch of Lanadelumab and will also provide the insight about how Lanadelumab will evolve in the market as well as within its respective class.Report provides detailed information of clinical trials that have been or are being conducted for this product. Analysis and Insightful information around the clinical trials is provided by assessment of the trial results.

Attribute analysis carried out by our analysts helps in understanding how the upcoming launch scores itself in comparison to other competitors (both marketed and pipeline). The scoring and analysis has been based upon scrutinizing data from all key clinical trials for the product. A head to head comparison with marketed products if available is scanned thoroughly. Further, analyzing data of other competitors with regards to the product also assists in proper scoring of the product in its space.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.


• Detailed product description including its chemical properties, molecule type and mechanism of action
• Detailed description of non-clinical and clinical studies for all the indications
• Patent expiry analysis of the drug along with other competitors in the market
• Forecasted sales till 2022
• Lanadelumab market positioning analysis
• Lanadelumab class share evolution

Report Introduction
Lanadelumab Overview
Lanadelumab of action
Pre-clinical Characterization
• Indication 1
• Indication 2
Clinical Characterization
• Indication 1
• Indication 2
Product Developmental Activities
• Collaboration
• Mergers & Acquisitions
• Financing
Lanadelumab Market Evolution
Lanadelumab Class Share Evolution
Lanadelumab Market Positioning
Patent Expiry Analysis
Competitive Landscape for the Lanadelumab in major indications

List of Tables

Table 1: Lanadelumab, Heat Map
Table 2: Clinical Trial Landscape
Table 3: Clinical Efficacy Data from Cross Trials
Table 4: Competitive Landscape for Lanadelumab in Indication 1
Table 5: Competitive Landscape for Lanadelumab in Indication 2

List of Figures

Figure 1: Lanadelumab Developmental Milestones
Figure 2: Lanadelumab Sales Forecast till 2023
Figure 3: Lanadelumab Class Share Evolution
Figure 4: Comparative analysis of Lanadelumab with marketed products in the same class
Figure 5: Patent Expiry Analysis


Added to Cart

Electronic (PDF)
This license allows only one user to access the PDF.

Electronic (PDF)
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
Lukasiewicz Research Network